Diversify Advisory Services LLC Decreases Stock Position in Hims & Hers Health, Inc. $HIMS

Diversify Advisory Services LLC trimmed its stake in shares of Hims & Hers Health, Inc. (NYSE:HIMS) by 62.0% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 13,769 shares of the company’s stock after selling 22,449 shares during the quarter. Diversify Advisory Services LLC’s holdings in Hims & Hers Health were worth $781,000 at the end of the most recent quarter.

A number of other hedge funds also recently bought and sold shares of HIMS. Quent Capital LLC purchased a new position in shares of Hims & Hers Health in the 3rd quarter valued at about $28,000. Virtus Advisers LLC acquired a new stake in Hims & Hers Health in the second quarter valued at approximately $26,000. Hilltop National Bank acquired a new stake in Hims & Hers Health in the third quarter valued at approximately $35,000. Skandinaviska Enskilda Banken AB publ lifted its stake in Hims & Hers Health by 408.2% in the second quarter. Skandinaviska Enskilda Banken AB publ now owns 747 shares of the company’s stock worth $37,000 after acquiring an additional 600 shares during the last quarter. Finally, Smartleaf Asset Management LLC lifted its stake in Hims & Hers Health by 44.7% in the third quarter. Smartleaf Asset Management LLC now owns 916 shares of the company’s stock worth $54,000 after acquiring an additional 283 shares during the last quarter. Institutional investors and hedge funds own 63.52% of the company’s stock.

Hims & Hers Health Stock Performance

Shares of Hims & Hers Health stock opened at $25.89 on Thursday. The company has a quick ratio of 1.70, a current ratio of 1.90 and a debt-to-equity ratio of 1.80. Hims & Hers Health, Inc. has a 52 week low of $13.74 and a 52 week high of $70.43. The firm’s 50 day moving average is $24.18 and its two-hundred day moving average is $37.66. The firm has a market capitalization of $5.90 billion, a P/E ratio of 50.76, a P/E/G ratio of 4.55 and a beta of 2.55.

Hims & Hers Health (NYSE:HIMS) last issued its quarterly earnings data on Monday, February 23rd. The company reported $0.08 earnings per share for the quarter, topping the consensus estimate of $0.02 by $0.06. Hims & Hers Health had a net margin of 5.47% and a return on equity of 22.48%. The business had revenue of $617.82 million during the quarter, compared to the consensus estimate of $619.48 million. During the same quarter in the previous year, the firm earned $0.11 EPS. The company’s revenue was up 28.4% compared to the same quarter last year. Research analysts forecast that Hims & Hers Health, Inc. will post 0.29 EPS for the current fiscal year.

Hims & Hers Health announced that its board has authorized a stock buyback plan on Monday, November 17th that permits the company to repurchase $250.00 million in shares. This repurchase authorization permits the company to purchase up to 3% of its shares through open market purchases. Shares repurchase plans are typically a sign that the company’s management believes its shares are undervalued.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on HIMS. BTIG Research downgraded shares of Hims & Hers Health from a “buy” rating to a “neutral” rating in a research report on Tuesday, February 24th. TD Cowen decreased their price objective on shares of Hims & Hers Health from $20.00 to $17.00 and set a “hold” rating for the company in a research report on Tuesday, February 24th. Leerink Partners lowered their target price on shares of Hims & Hers Health from $20.00 to $17.50 and set a “market perform” rating for the company in a research note on Tuesday, February 24th. Needham & Company LLC raised Hims & Hers Health from a “hold” rating to a “buy” rating and set a $30.00 target price on the stock in a report on Monday. Finally, Truist Financial restated a “hold” rating and issued a $18.00 price target (down from $37.00) on shares of Hims & Hers Health in a research note on Tuesday, February 24th. Three investment analysts have rated the stock with a Buy rating, thirteen have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $30.75.

Key Headlines Impacting Hims & Hers Health

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: Landmark Novo Nordisk partnership — the deal replaces compounded GLP‑1 sales with distribution of branded Wegovy/Ozempic (including new pill forms), materially reducing legal risk and legitimizing HIMS’ platform; analysts and market commentary see this as transformational for revenue and margins. Read More. Read More.
• Positive Sentiment: Analyst upgrades and higher price targets — multiple firms (Barclays, Needham, Deutsche Bank and others) have raised ratings/targets after the Novo news, supporting upside and prompting fresh buy interest. Read More. Read More.
• Positive Sentiment: Large call‑option activity — unusually heavy call buying (322k calls, ~128% above normal) signals speculative and directional bullish positioning that can amplify intraday moves and volatility. Read More.
• Neutral Sentiment: Strong 2025 operating results provide context — HIMS reported $2.35B revenue (+59% YoY), solid EBITDA and cash flow, and 2.5M+ subscribers with improving ARPU/cross‑sell metrics, which support a longer‑term bull case but leave execution risk. Read More.
• Neutral Sentiment: Corporate hire and platform expansion — appointment of a new Chief Communications Officer and product/platform expansions are governance/brand positives but are longer‑dated catalysts. Read More.
• Neutral Sentiment: Mixed brokerage consensus — while a number of firms upgraded, the street average rating remains around “Hold,” so fresh positive headlines may be needed to sustain multiple expansion. Read More.
• Negative Sentiment: Some institutional selling noted — at least one asset manager trimmed/exit positions despite the deal; this could add supply and headwinds if other holders follow. Read More.

Insider Transactions at Hims & Hers Health

In related news, CFO Oluyemi Okupe sold 9,067 shares of the business’s stock in a transaction on Tuesday, January 20th. The shares were sold at an average price of $30.34, for a total value of $275,092.78. Following the completion of the sale, the chief financial officer directly owned 91,617 shares of the company’s stock, valued at $2,779,659.78. The trade was a 9.01% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, COO Michael Chi sold 13,750 shares of the company’s stock in a transaction on Wednesday, December 17th. The shares were sold at an average price of $36.71, for a total transaction of $504,762.50. Following the completion of the transaction, the chief operating officer owned 305,161 shares of the company’s stock, valued at $11,202,460.31. This represents a 4.31% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 80,463 shares of company stock valued at $2,846,696 over the last quarter. 13.71% of the stock is owned by corporate insiders.

About Hims & Hers Health

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.